Associations of Metabolic Dysfunction–Associated Fatty Liver Disease With Peripheral Artery Disease: Prospective Analysis in the UK Biobank and ARIC Study

Abstract

Background There is currently limited evidence comparing the association between metabolic dysfunction–associated fatty liver disease (MAFLD), nonalcoholic fatty liver disease (NAFLD), and the risk of peripheral artery disease (PAD). This study aims to analyze the associations of MAFLD and NAFLD with incident PAD. Methods and Results Two longitudinal studies, the UKB (UK Biobank) study (n=372 216) and the ARIC (Atherosclerosis Risk in Communities) study (n=4681), categorized participants into MAFLD/non‐MAFLD groups and NAFLD/non‐NAFLD groups. Subsequently, participants were classified into 4 groups: non–fatty liver disease, MAFLD‐only, NAFLD‐only, and both MAFLD and NAFLD groups. Cox proportional hazard model estimated associations of MAFLD/NAFLD status, subtypes, and liver fibrosis severity with PAD risk. The MAFLD group had a higher risk of incident PAD compared with the non‐MAFLD group, and similarly, the NAFLD group had a higher risk compared with the non‐NAFLD group. Among these 4 groups, the MAFLD‐only group had the strongest association with the risk of incident PAD, while the NAFLD‐only group was not independently associated. Diabetic MAFLD subtype was significantly associated with increased PAD risk, and higher level of liver fibrosis scores correlated with elevated PAD risk. Conclusions Both MAFLD and NAFLD are significantly associated with an increased incidence of PAD, with stronger associations in MAFLD and diabetic MAFLD population. These findings emphasize that the need for screening and prevention strategies for PAD in this high‐risk population is warranted. The assessment of MAFLD and its subtypes should be considered as an integral component of cardiovascular risk assessment.

Keywords

• ARIC
• metabolic dysfunction–associated fatty liver disease
• nonalcoholic fatty liver disease
• peripheral artery disease
• UK Biobank